Does Lacosamide Reduce Hypertension?
Lacosamide, sold as Vimpat, is an anticonvulsant that treats partial-onset seizures and primary generalized tonic-clonic seizures. It does not reduce hypertension and lacks FDA approval or clinical evidence for this use.[1]
How Lacosamide Modifies Sodium Channels
Lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels (VGSCs), particularly Nav1.1, Nav1.2, Nav1.3, and Nav1.6. This reduces pathological high-frequency neuronal firing without broadly blocking fast inactivation, unlike traditional sodium channel blockers such as carbamazepine or phenytoin.[2][3] The drug binds to the auxiliary collapsin response mediator protein 2 (CRMP-2), stabilizing slow inactivation states and limiting repetitive action potentials in hyperexcitable neurons.
Why It Does Not Reduce Hypertension
Hypertension involves vascular smooth muscle contraction and renin-angiotensin system activation, not sodium channel hyperexcitability in neurons. Lacosamide's VGSC effects target central nervous system neurons, not cardiovascular ion channels like L-type calcium or vascular sodium channels. No mechanism links its sodium channel modulation to blood pressure lowering; clinical trials and post-marketing data report no antihypertensive effects.[1][4]
Observed Cardiovascular Effects
Lacosamide can cause dose-dependent PR interval prolongation on ECG due to atrioventricular node conduction slowing via sodium channel effects in cardiac tissue. This raises risks of bradycardia or AV block at high doses (>400 mg/day), but it does not lower systemic blood pressure.[5] Hypertension appears in adverse event reports as a comorbidity, not a treatment outcome.
Alternatives for Seizure Control with Blood Pressure Benefits
For patients with epilepsy and hypertension, drugs like lamotrigine or levetiracetam avoid cardiac effects. Antihypertensives such as ACE inhibitors or calcium channel blockers (e.g., amlodipine) target vascular tone directly. Consult a physician for combined management.
[1]: FDA Label for Vimpat (lacosamide)
[2]: Errington et al., Neuropharmacology (2008). "Mechanism of action of lacosamide."
[3]: Beyreiss et al., CNS Drugs (2021). "Lacosamide: Pharmacology review."
[4]: UCB Pharma clinical trials database (ClinicalTrials.gov).
[5]: Stephen et al., Epilepsy Research (2019). "Cardiac effects of lacosamide."